{"id":"NCT03038100","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","officialTitle":"A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-08","primaryCompletion":"2022-02-08","completion":"2022-08-12","firstPosted":"2017-01-31","resultsPosted":"2023-02-17","lastUpdate":"2023-02-17"},"enrollment":1301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Neoplasms"],"interventions":[{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Atezolizumab","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":[]},{"type":"DRUG","name":"Atezolizumab Placebo","otherNames":[]}],"arms":[{"label":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab","type":"EXPERIMENTAL"},{"label":"Placebo With Paclitaxel, Carboplatin and Bevacizumab","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population","timeFrame":"From randomization until disease progression or death from any cause (up to approximately 55 months)","effectByArm":[{"arm":"Placebo With Paclitaxel, Carboplatin and Bevacizumab","deltaMin":18.37,"sd":null},{"arm":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab","deltaMin":19.48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2785"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":268,"countries":["United States","Australia","Austria","Belgium","Brazil","China","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Japan","Norway","Poland","Russia","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["37625235","36595569","33891472","30630885"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":304,"n":642},"commonTop":["ALOPECIA","NAUSEA","ARTHRALGIA","ANAEMIA","FATIGUE"]}}